Biomarkers of chronic inflammatory state in uremia and cardiovascular disease

International Journal of Inflammation

Volumn 2012, Issue , 2012, Pages

  Panichi, Vincenzo ^a   Scatena, Alessia ^a   Migliori, Massimiliano ^a   Marchetti, Valentina ^a   Paoletti, Sabrina ^a   Beati, Sara ^a  

^a Versilia Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 ANTIGEN; CD40 LIGAND; INTERLEUKIN 6; PENTRAXIN 3; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHRONIC INFLAMMATION; CORONARY ARTERY DISEASE; HUMAN; KIDNEY FAILURE; MORBIDITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UREMIA;

EID: 84867164866     PISSN: 20908040     EISSN: 20420099     Source Type: Journal    
DOI: 10.1155/2012/360147     Document Type: Review

References (58)

1. Stenvinkel P., Inflammation in end-stage renal diseasea fire that burns within. Contributions to Nephrology 2005 149 185 199 2-s2.0-20544477223 10.1159/000085525 (Pubitemid 43265016)
2. Zimmermann J., Herrlinger S., Pruy A., Metzger T., Wanner C., Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney International 1999 55 2 648 658 2-s2.0-0032935896 10.1046/j.1523-1755.1999.00273.x (Pubitemid 29082891)
3. Ridker P. M., Cushman M., Stampfer M. J., Tracy R. P., Hennekens C. H., Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New England Journal of Medicine 1997 336 14 973 979 2-s2.0-0030956673 10.1056/NEJM199704033361401 (Pubitemid 27152782)
4. Danesh J., Collins R., Appleby P., Peto R., Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. Journal of the American Medical Association 1998 279 18 1477 1482 2-s2.0-0032513756 10.1001/jama.279.18.1477 (Pubitemid 28228207)
5. Danesh J., Whincup P., Walker M., Lennon L., Thomson A., Appleby P., Gallimore J. R., Pepys M. B., Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. British Medical Journal 2000 321 7255 199 204 2-s2.0-0034702485 (Pubitemid 30459555)
6. Albert C. M., Ma J., Rifai N., Stampfer M. J., Ridker P. M., Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002 105 22 2595 2599 2-s2.0-0037024228 10.1161/01.CIR.0000017493.03108.1C (Pubitemid 34596034)
7. Harris T. B., Ferrucci L., Tracy R. P., Corti M. C., Wacholder S., Ettinger W. H., Heimovitz H., Cohen H. J., Wallace R., Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. American Journal of Medicine 1999 106 5 506 512 2-s2.0-0033134682 10.1016/S0002-9343(99)00066-2 (Pubitemid 29231100)
8. Ridker P. M., Stampfer M. J., Rifai N., Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. Journal of the American Medical Association 2001 285 19 2481 2485 2-s2.0-0035897688 (Pubitemid 32433842)
9. Ridker P. M., Rifai N., Rose L., Buring J. E., Cook N. R., Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. New England Journal of Medicine 2002 347 20 1557 1565 2-s2.0-0037078969 10.1056/NEJMoa021993 (Pubitemid 35315836)
10. Ridker P. M., High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001 103 13 1813 1818 2-s2.0-0035799331 (Pubitemid 32291421)
11. Biasucci L. M., C-Reactive Protein and secondary prevention of coronary events. Clinica Chimica Acta 2001 311 1 49 52 2-s2.0-0035885026 10.1016/S0009-8981(01)00558-7 (Pubitemid 32835209)
12. Haverkate F., Thompson S. G., Pyke S. D. M., Gallimore J. R., Pepys M. B., Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997 349 9050 462 466 2-s2.0-0031054058 10.1016/S0140-6736(96)07591-5 (Pubitemid 27077826)
13. Lindahl B., Toss H., Siegbahn A., Venge P., Wallentin L., Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. New England Journal of Medicine 2000 343 16 1139 1147 2-s2.0-0034687438 10.1056/NEJM200010193431602
14. Ridker P. M., Rifai N., Pfeffer M. A., Sacks F. M., Moye L. A., Goldman S., Flaker G. C., Braunwald E., Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998 98 9 839 844 2-s2.0-0032169240 (Pubitemid 28397432)
15. Milazzo D., Biasucci L. M., Luciani N., Martinelli L., Canosa C., Schiavello R., Maseri A., Possati G., Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events. American Journal of Cardiology 1999 84 4 459 461 2-s2.0-0033566649 10.1016/S0002-9149(99)00333-1 (Pubitemid 29398669)
16. Bickel C., Rupprecht H. J., Blankenberg S., Espiniola-Klein C., Schlitt A., Rippin G., Hafner G., Treude R., Othman H., Hofmann K. P., Meyer J., Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. American Journal of Cardiology 2002 89 8 901 908 2-s2.0-0037090366 10.1016/S0002-9149(02)02236-1 (Pubitemid 34310284)
17. De Sutter J., De Buyzere M., Gheeraert P., Van de Wiele C., Voet J., De Pauw M., Dierckx R., De Backer G., Taeymans Y., Fibrinogen and C-reactive protein on admission as markers of final infarct size after primary angioplasty for acute myocardial infarction. Atherosclerosis 2001 157 1 189 196 2-s2.0-0034966496 10.1016/S0021-9150(00)00703-6 (Pubitemid 32539370)
18. Bazzino O., Ferreirós E. R., Pizarro R., Corrado G., C-reactive protein and the stress tests for the risk stratification of patients recovering from unstable angina pectoris. American Journal of Cardiology 2001 87 11 1235 1239 2-s2.0-0035370496 10.1016/S0002-9149(01)01511-9 (Pubitemid 32493861)
19. Zebrack J. S., Anderson J. L., Maycock C. A., Horne B. D., Bair T. L., Muhlestein J. B., Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. American Journal of Cardiology 2002 89 2 145 149 2-s2.0-0037081679 10.1016/S0002- 9149(01)02190-7 (Pubitemid 34132900)
20. Zebrack J. S., Muhlestein J. B., Horne B. D., Anderson J. L., C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. Journal of the American College of Cardiology 2002 39 4 632 637 2-s2.0-0037138517 10.1016/S0735-1097(01)01804-6 (Pubitemid 34158159)
21. Stenvinkel P., Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. Blood Purification 2001 19 2 143 151 2-s2.0-0035164901 10.1159/000046932 (Pubitemid 32041345)
22. Brancaccio D., Ciro Tetta M. G., Panichi V., Inflammation, CRP, calcium overload and a high calcium-phosphate product: a liaison dangereuse Nephrology Dialysis Transplantation 2002 17 2 201 203 2-s2.0-0036175233 (Pubitemid 34157128)
23. Ikizler T. A., Wingard R. L., Harvell J., Shyr Y., Hakim R. M., Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney International 1999 55 5 1945 1951 2-s2.0-0032920541 10.1046/j.1523-1755.1999.00410.x (Pubitemid 29197983)
24. Wollert K. C., Drexler H., The role of interleukin-6 in the failing heart. Heart Failure Reviews 2001 6 2 95 103 2-s2.0-0035058586 10.1023/A:1011401825680 (Pubitemid 32328172)
25. Wanner C., Zimmermann J., Schwedler S., Metzger T., Inflammation and cardiovascular risk in dialysis patients. Kidney International, Supplement 2002 61 80 S99 S102 2-s2.0-0035999931 (Pubitemid 34534168)
26. US Renal Data System, Excerpts from the USRDS 2001 annual data report. American Journal of Kidney Disease 2001 38 S1 S248
27. Panichi V., Migliori M., De Pietro S., Taccola D., Andreini B., Metelli M. R., Giovannini L., Palla R., The link of biocompatibility to cytokine production. Kidney International 2000 58 76 S96 S103 2-s2.0-0033853590 (Pubitemid 30612808)
28. Zhang L., Kao W. H. L., Berthier-Schaad Y., Plantinga L., Fink N., Smith M. W., Coresh J., C-reactive protein haplotype predicts serum C-reactive protein levels but not cardiovascular disease risk in a dialysis cohort. American Journal of Kidney Diseases 2007 49 1 118 126 2-s2.0-33845571244 10.1053/j.ajkd.2006.10.008 (Pubitemid 44932197)
29. Liu Y., Berthier-Schaad Y., Fallin M. D., Fink N. E., Tracy R. P., Klag M. J., Smith M. W., Coref J., Coref J., IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. Journal of the American Society of Nephrology 2006 17 3 863 870 2-s2.0-33645450879 10.1681/ASN.2005050465
30. Kimmel P. L., Phillips T. M., Simmens S. J., Peterson R. A., Weihs K. L., Alleyne S., Cruz I., Yanovski J. A., Veis J. H., Immunologic function and survival in hemodialysis patients. Kidney International 1998 54 1 236 244 2-s2.0-0031835451 10.1046/j.1523-1755.1998.00981.x (Pubitemid 28288040)
31. Schönbeck U., Libby P., CD40 signaling and plaque instability. Circulation Research 2001 89 12 1092 1103 2-s2.0-0035824895 (Pubitemid 34627866)
32. Mach F., Schönbeck U., Sukhova G. K., Bourcier T., Bonnefoy J. Y., Pober J. S., Libby P., Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America 1997 94 5 1931 1936 2-s2.0-0031049711 10.1073/pnas.94.5.1931 (Pubitemid 27113939)
33. Graf D., Müller S., Korthäuer U., Van Kooten C., Weise C., Kroczek R. A., A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. European Journal of Immunology 1995 25 6 1749 1754 2-s2.0-0029051542 10.1002/eji.1830250639
34. Desideri G., Ferri C., Effects of obesity and weight loss on soluble CD40L levels. Journal of the American Medical Association 2003 289 14 1781 1782 2-s2.0-0037502808 10.1001/jama.289.14.1781 (Pubitemid 37430244)
35. Cipollone F., Mezzetti A., Porreca E., Di Febbo C., Nutini M., Fazia M., Falco A., Cuccurullo F., Davì G., Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002 106 4 399 402 2-s2.0-0037162340 10.1161/01.CIR. 0000025419.95769.F0 (Pubitemid 34803680)
36. Cipollone F., Chiarelli F., Davì G., Ferri C., Desideri G., Fazia M., Iezzi A., Santilli F., Pini B., Cuccurullo C., Tumini S., Del Ponte A., Santucci A., Cuccurullo F., Mezzetti A., Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 2005 48 6 1216 1224 2-s2.0-21344458137 10.1007/s00125-005-1750-2 (Pubitemid 40909659)
37. Santilli F., Davì G., Consoli A., Cipollone F., Mezzetti A., Falco A., Taraborelli T., Devangelio E., Ciabattoni G., Basili S., Patrono C., Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. Journal of the American College of Cardiology 2006 47 2 391 397 2-s2.0-30344483664 10.1016/j.jacc.2005.03.079 (Pubitemid 43063260)
38. Aukrust P., Müller F., Ueland T., Berget T., Aaser E., Brunsvig A., Solum N. O., Forfang K., Froland S. S., Gullestad L., Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999 100 6 614 620 2-s2.0-0344850187 (Pubitemid 29379750)
39. Schönbeck U., Varo N., Libby P., Buring J., Ridker P. M., Soluble CD40L and cardiovascular risk in women. Circulation 2001 104 19 2266 2268 2-s2.0-0035818509 (Pubitemid 33049505)
40. Heeschen C., Dimmeler S., Hamm C. W., Van den Brand M. J., Boersma E., Zeiher A. M., Simoons M. L., Soluble CD40 ligand in acute coronary syndromes. New England Journal of Medicine 2003 348 12 1104 1111 2-s2.0-0037456769 10.1056/NEJMoa022600 (Pubitemid 36337321)
41. Cipollone F., Ferri C., Desideri G., Paloscia L., Materazzo G., Mascellanti M., Fazia M., Iezzi A., Cuccurullo C., Pini B., Bucci M., Santucci A., Cuccurullo F., Mezzetti A., Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation 2003 108 22 2776 2782 2-s2.0-10744230698 10.1161/01.CIR.0000103700.05109.0D (Pubitemid 37498980)
42. Hocher B., Liefeldt L., Quaschning T., Kalk P., Ziebig R., Godes M., Relle K., Asmus G., Stasch J. P., Soluble CD154 is a unique predictor of nonfatal and fatal atherothrombotic events in patients who have end-stage renal disease and are on hemodialysis. Journal of the American Society of Nephrology 2007 18 4 1323 1330 2-s2.0-34047201108 10.1681/ASN.2006070684 (Pubitemid 46536919)
43. Desideri G., Panichi V., Paoletti S., Soluble CD40 ligand is predictive of combined cardiovascular morbidity and mortality in patients on haemodialysis at a relatively short-term follow-up. Nephrology, Dialysis and Transplantion 2011 26 9 2983 2988
44. Sirolli V., Strizzi L., Di Stante S., Robuffo I., Procopio A., Bonomini M., Platelet activation and platelet-erythrocyte aggregates in end-stage renal disease patients on hemodialysis. Thrombosis and Haemostasis 2001 86 3 834 839 2-s2.0-0034856781 (Pubitemid 32834194)
45. Tripepi G., Mallamaci F., Zoccali C., Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. Journal of the American Society of Nephrology 2005 16 3 S83 S88 2-s2.0-20844445415 10.1681/ASN.2004110972 (Pubitemid 41725091)
46. Wiswedel I., Hirsch D., Carluccio F., Hampl H., Siems W., F2-Isoprostanes as biomarkers of lipid peroxidation in patients with chronic renal failure. BioFactors 2005 24 14 201 208 2-s2.0-28644451178 (Pubitemid 41750543)
47. Desideri G., Ferri C., Endothelial activation. Sliding door to atherosclerosis. Current Pharmaceutical Design 2005 11 17 2163 2175 2-s2.0-21044445494 10.2174/1381612054367382 (Pubitemid 40872707)
48. Steel D. M., Whitehead A. S., The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunology Today 1994 15 2 81 88 2-s2.0-0027952502 10.1016/0167-5699(94)90138-4 (Pubitemid 24049801)
49. Mantovani A., Garlanda C., Doni A., Bottazzi B., Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. Journal of Clinical Immunology 2008 28 1 1 13 2-s2.0-38149021434 10.1007/s10875-007-9126-7
50. Suliman M. E., Yilmaz M. I., Carrero J. J., Qureshi A. R., Saglam M., Ipcioglu O. M., Yenicesu M., Tong M., Heimbürger O., Barany P., Alvestrand A., Lindholm B., Stenvinkel P., Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clinical Journal of the American Society of Nephrology 2008 3 4 976 985 2-s2.0-42949175399 10.2215/CJN.03960907
51. Bottazzi B., Bastone A., Doni A., Garlanda C., Valentino S., Deban L., Maina V., Cotena A., Moalli F., Vago L., Salustri A., Romani L., Mantovani A., The long pentraxin PTX3 as a link among innate immunity, inflammation, and female fertility. Journal of Leukocyte Biology 2006 79 5 909 912 2-s2.0-33745313564 10.1189/jlb.1005557 (Pubitemid 44835576)
52. He X., Han B., Liu M., Long pentraxin 3 in pulmonary infection and acute lung injury. American Journal of Physiology 2007 292 5 L1039 L1049 2-s2.0-34447542024 10.1152/ajplung.00490.2006 (Pubitemid 47084848)
53. Mantovani A., Garlanda C., Bottazzi B., Peri G., Doni A., Martinez de la Torre Y., Latini R., The long pentraxin PTX3 in vascular pathology. Vascular Pharmacology 2006 45 5 326 330 2-s2.0-33751093796 10.1016/j.vph.2006.08.011 (Pubitemid 44765293)
54. Stehouwer C. D. A., Smulders Y. M., Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. Journal of the American Society of Nephrology 2006 17 8 2106 2111 2-s2.0-33746473003 10.1681/ASN.2005121288 (Pubitemid 44141899)
55. Gerstein H. C., Mann J. F. E., Yi Q., Zinman B., Dinneen S. F., Hoogwerf B., Hallé J. P., Young J., Rashkow A., Joyce C., Nawaz S., Yusuf S., Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. Journal of the American Medical Association 2001 286 4 421 426 2-s2.0-0035948631 (Pubitemid 32681484)
56. Latini R., Maggioni A. P., Peri G., Gonzini L., Lucci D., Mocarelli P., Vago L., Pasqualini F., Signorini S., Soldateschi D., Tarli L., Schweiger C., Fresco C., Cecere R., Tognoni G., Mantovani A., Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004 110 16 2349 2354 2-s2.0-6444223701 10.1161/01.CIR.0000145167.30987.2E (Pubitemid 39407338)
57. Barbui T., Carobbio A., Finazzi G., Vannucchi A. M., Barosi G., Antonioli E., Guglielmelli P., Pancrazzi A., Salmoiraghi S., Zilio P., Ottomano C., Marchioli R., Cuccovillo I., Bottazzi B., Mantovani A., Rambaldi A., Inflammation and thrombosis in essential thrombocythemia and polycythemia vera different role of C-reactive protein and pentraxin 3. Haematologica 2011 96 2 315 318 2-s2.0-79551644817 10.3324/haematol.2010.031070
58. Suliman M. E., Qureshi A. R., Carrero J. J., Bárány P., Yilmaz M. I., Snaedal-Jonsdottir S., Alvestrand A., Heimbürger O., Lindholm B., Stenvinkel P., The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality. Monthly Journal of the Association of Physicians 2008 101 5 397 405 2-s2.0-42949148076 10.1093/qjmed/hcn019 (Pubitemid 351619248)